Ensign Group (ENSG) Valuation Check After Robust Earnings Beat And Ongoing Growth Expectations

Recent fourth quarter earnings at Ensign Group (ENSG) surprised to the upside on margins and adjusted EPS. This has prompted investors to reassess what the current share price already reflects about its growth potential.

See our latest analysis for Ensign Group.

The latest 1-day share price return of 1.22% takes Ensign Group to US$200.39, while a 12.34% 90-day share price return and 62.17% 1-year total shareholder return indicate that momentum has been building around its earnings story and perceived risk profile.

If strong execution in healthcare services has your attention, it can be a smart moment to broaden your watchlist with other quality names via the 37 healthcare AI stocks

With Ensign Group now at US$200.39 and trading at roughly a 10% discount to the latest analyst price target of US$220.40, the key question is simple: is there still a buying opportunity here, or is future growth already priced in?

Price-to-Earnings of 34x: Is it justified?

On a P/E of 34x at a last close of $200.39, Ensign Group screens as expensive compared with both its own fair ratio and sector benchmarks.

The P/E ratio compares the current share price with earnings per share and is a quick way to see how much investors are paying for each dollar of profit. For a healthcare operator with established earnings, this multiple often reflects how confident the market is about the durability of current profits and the pace of future growth.

Here, the market is assigning Ensign Group a P/E of 34x, which sits well above the estimated fair P/E of 26.9x that the fair ratio suggests the price could move toward. It is also higher than the peer average P/E of 16.2x and the broader US Healthcare industry average of 21.8x. This indicates that investors are pricing in a stronger earnings profile than both peers and the sector overall.

Explore the SWS fair ratio for Ensign Group

Result: Price-to-Earnings of 34x (OVERVALUED)

However, investors also need to weigh risks related to the rich expectations embedded in a 34x P/E, as well as any potential pressure on margins in skilled nursing operations.

Find out about the key risks to this Ensign Group narrative.

Another View: What Does The Cash Flow Say?

While the 34x P/E points to an expensive stock, the SWS DCF model goes further by valuing Ensign Group’s future cash flows at $147.01 per share, compared with the current $200.39 price. That gap suggests investors are paying a clear premium. The key question is whether the quality story justifies that extra cash.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ensign Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 61 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of optimism and valuation risk has you thinking, act while the data is fresh and weigh the upside yourself with the 2 key rewards.

Ready to uncover more investment ideas?

If Ensign Group has sharpened your focus on quality, now is the moment to widen your opportunity set across different styles instead of stopping at a single name.

• Target resilient income by reviewing companies with 5%+ yields screened as 13 dividend fortresses
• Hunt for quality at a discount by checking stocks filtered as 61 high quality undervalued stocks
• Prioritise balance sheet strength by scanning companies in the solid balance sheet and fundamentals stocks screener (40 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com